Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Viswanatha Reddy

Internal Medicine Benson, NC Medical Doctor

NPI 1184663734 CMS profile 189434

1 Medical Dr, Benson, NC 27504

Open in the dashboard

General payments

$13,077

693 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Viswanatha Reddy of Benson, NC is reported in the CMS Open Payments database as having received $13,077 across 693 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,365 73
2024 General $1,412 75
2023 General $1,746 106
2022 General $2,995 109
2021 General $2,587 141
2020 General $1,587 108
2019 General $1,386 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Viswanatha Reddy
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Viswanatha Reddy were reported at $1,365. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Viswanatha Reddy Internal Medicine median Middle half National median
2019 $1,386 $159 $48–$570 $163
2020 $1,587 $119 $33–$402 $114
2021 $2,587 $135 $37–$521 $132
2022 $2,995 $141 $42–$496 $149
2023 $1,746 $149 $45–$519 $160
2024 $1,412 $154 $47–$537 $164
2025 $1,365 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Preventric Diagnostics, Inc. $1,183 2 payments
  2. Amgen Inc. $952 71 payments
  3. AbbVie, Inc. $843 52 payments
  4. Esperion Therapeutics, Inc. $814 16 payments
  5. Janssen Pharmaceuticals, Inc $769 50 payments
  6. Novo Nordisk Inc $750 53 payments
  7. Pfizer Inc. $621 40 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $535 29 payments
  9. Novartis Pharmaceuticals Corporation $491 30 payments
  10. Corcept Therapeutics $446 14 payments
  11. Other $5,673 336 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,037 690 payments
  2. Education $41 3 payments
Products named General payments · program years 2019–2025
  1. BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM $1,183 2 payments
  2. NEXLETOL $814 16 payments
  3. NEXLIZET $543 6 payments
  4. Kerendia $535 29 payments
  5. XARELTO $518 33 payments
  6. AIMOVIG $481 31 payments
  7. Korlym $446 14 payments
  8. Repatha $442 42 payments
  9. RYBELSUS $439 26 payments
  10. Ozempic $385 32 payments
  11. Other $10,916 697 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 237 drugs

Part D claims

26,194

Median for Internal Medicine: 777

Drug cost

$2,060,272

Median for Internal Medicine: $73,373

Branded share of claims

22.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 339 $231,275
Ozempic Semaglutide Brand 191 $200,742
Mounjaro Tirzepatide Brand 140 $156,388
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 167 $138,321
Xarelto Rivaroxaban Brand 194 $126,382
Jardiance Empagliflozin Brand 136 $120,802
Trulicity Dulaglutide Brand 113 $114,771
Linzess Linaclotide Brand 87 $59,148
Gemtesa Vibegron Brand 65 $43,672
Farxiga Dapagliflozin Propanediol Brand 55 $41,844

The 10 drugs with the highest cost, of 237 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 191 billing codes

Paid by Medicare

$425,972

Of which drugs: $46,518

Medicare patients

479

Average age 73

Services billed

19,921

259 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 47%
Chronic kidney disease 36%
Osteoporosis 35%
Depression 32%
Ischemic heart disease 30%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for Hepatitis B adult dosage (2 dose schedule) injection into muscle 90739 Office 22 32 $5,050
Pcv20 vaccine im 90677 Office 11 11 $2,921
Injection, regadenoson, 0.1 mg J2785 Office 27 108 $586
Injection, methylprednisolone acetate, 1 mg J1010 Office 34 4,120 $409
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 36 1,375 $305
Injection, ceftriaxone sodium, per 250 mg J0696 Office 50 304 $100
Injection, methylprednisolone sodium succinate, up to 125 mg J2930 Office 25 26 $98
Infusion, normal saline solution , 1000 cc J7030 Office 29 40 $83
Injection, methylprednisolone acetate, 80 mg J1040 Office 11 13 $69
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 25 33 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $144
$144 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $135
$135 65 —
Korlym
  • Corcept Therapeutics $116
$116 — —
UBRELVY
  • AbbVie, Inc. $66
$66 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

693 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record